EA200970164A1 - Ингибиторы каспазы на основе пиридазинонового каркаса - Google Patents

Ингибиторы каспазы на основе пиридазинонового каркаса

Info

Publication number
EA200970164A1
EA200970164A1 EA200970164A EA200970164A EA200970164A1 EA 200970164 A1 EA200970164 A1 EA 200970164A1 EA 200970164 A EA200970164 A EA 200970164A EA 200970164 A EA200970164 A EA 200970164A EA 200970164 A1 EA200970164 A1 EA 200970164A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyridasinone
carcass
caspase inhibitors
inhibitors based
caspase
Prior art date
Application number
EA200970164A
Other languages
English (en)
Other versions
EA015886B1 (ru
Inventor
Хие-Киунг Чанг
Йеонг-Соо Ох
Ионг Дзин Дзанг
Original Assignee
Эл Джи Лайф Сайенсиз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эл Джи Лайф Сайенсиз Лтд. filed Critical Эл Джи Лайф Сайенсиз Лтд.
Publication of EA200970164A1 publication Critical patent/EA200970164A1/ru
Publication of EA015886B1 publication Critical patent/EA015886B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Настоящее изобретение относится к производному пиридазинона, которое можно использовать в качестве ингибитора каспазы, к способу его получения и включающей его фармацевтической композиции для ингибирования каспазы.
EA200970164A 2006-08-02 2007-07-27 Ингибиторы каспазы на основе пиридазинонового каркаса EA015886B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20060073029 2006-08-02
PCT/KR2007/003617 WO2008016239A1 (en) 2006-08-02 2007-07-27 Caspase inhibitors based on pyridazinone scaffold

Publications (2)

Publication Number Publication Date
EA200970164A1 true EA200970164A1 (ru) 2009-08-28
EA015886B1 EA015886B1 (ru) 2011-12-30

Family

ID=38997391

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970164A EA015886B1 (ru) 2006-08-02 2007-07-27 Ингибиторы каспазы на основе пиридазинонового каркаса

Country Status (13)

Country Link
US (1) US8481537B2 (ru)
EP (1) EP2046757A4 (ru)
JP (1) JP5102834B2 (ru)
KR (1) KR20080012176A (ru)
CN (1) CN101506174B (ru)
AU (1) AU2007279550B2 (ru)
BR (1) BRPI0715462A2 (ru)
CA (1) CA2659084C (ru)
CO (1) CO6160228A2 (ru)
EA (1) EA015886B1 (ru)
MX (1) MX2009001155A (ru)
NZ (1) NZ574791A (ru)
WO (1) WO2008016239A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
JP2012131708A (ja) * 2009-04-28 2012-07-12 Nissan Chem Ind Ltd ４位置換ピリダジノン化合物及びｐ２ｘ７受容体阻害剤
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
TW201607929A (zh) 2013-12-05 2016-03-01 拜耳作物科學公司 Ｎ－環烷基－ｎ－｛［２－（１－經取代環烷基）苯基］亞甲基｝－（硫代）甲醯胺衍生物
EP3077378B1 (en) 2013-12-05 2018-11-07 Bayer CropScience Aktiengesellschaft N-cyclopropyl-n-{[2-(1-substitutedcyclopropyl)phenyl]methylene}-(thio)carboxamide derivatives
WO2015153683A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
EP3180319B1 (en) * 2014-08-14 2018-10-03 F.Hoffmann-La Roche Ag Novel pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection
CN108997155A (zh) * 2018-09-17 2018-12-14 吉尔生化（上海）有限公司 一种多肽原料天冬氨酸β-叔丁酯α-甲酯盐酸盐的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2367862A1 (en) * 1999-03-16 2000-09-21 Merck Frosst Canada & Co. Gamma-ketoacid dipeptides as inhibitors of caspase-3
US7351702B2 (en) 2001-05-23 2008-04-01 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US20060069038A1 (en) 2003-02-07 2006-03-30 John Colucci Irreversible caspase-3 inhibitors as active site probes
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa

Also Published As

Publication number Publication date
BRPI0715462A2 (pt) 2014-05-06
CN101506174A (zh) 2009-08-12
AU2007279550B2 (en) 2012-08-09
CA2659084C (en) 2011-07-12
EP2046757A1 (en) 2009-04-15
JP5102834B2 (ja) 2012-12-19
US20090291959A1 (en) 2009-11-26
CN101506174B (zh) 2012-05-02
AU2007279550A1 (en) 2008-02-07
CO6160228A2 (es) 2010-05-20
EA015886B1 (ru) 2011-12-30
MX2009001155A (es) 2009-02-10
WO2008016239A1 (en) 2008-02-07
JP2009545585A (ja) 2009-12-24
CA2659084A1 (en) 2008-02-07
EP2046757A4 (en) 2011-04-27
US8481537B2 (en) 2013-07-09
KR20080012176A (ko) 2008-02-11
NZ574791A (en) 2011-12-22

Similar Documents

Publication Publication Date Title
SMP200900058B (it) Composti e composizioni come inibitori di proteinachinasi.
SM201000108A (it) Composti e composizioni come inibitori di proteinachinasi.
EA200970164A1 (ru) Ингибиторы каспазы на основе пиридазинонового каркаса
EA201070786A1 (ru) Бензофуропиримидиноны
WO2008055068A3 (en) Inhibitors of histone deacetylase
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
MA32934B1 (fr) Combinaisons inhibitrices hsp90
DE602007012133D1 (de) Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
WO2010044981A3 (en) Benzoquinoline inhibitors of vesicular monoamine transporter 2
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
EA201171151A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
WO2008063671A3 (en) Heterobicyclic metalloprotease inhibitors
NO20081636L (no) FAP - inhibitorer
BRPI0719008A2 (pt) Inibidores de vírus da hepatite c
WO2009155001A3 (en) Wnt protein signalling inhibitors
CR10755A (es) Compounds and compositions as protein kinase inhibitors
EA200601391A1 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
CL2011000604A1 (es) Compuestos derivados de multiheteroarilo, inhibidores de h-pgds, composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades inflamatorias y alergicas.
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU